Association between prediagnostic prostate-specific antigen and prostate cancer probability in Black and non-Hispanic White men
© 2023 American Cancer Society..
BACKGROUND: Although Black men are more likely than non-Hispanic White men to develop and die from prostate cancer, limited data exist to guide prostate-specific antigen (PSA) screening protocols in Black men. This study investigated whether the risk for prostate cancer was higher than expected among self-identified Black than White veterans based on prebiopsy PSA level.
METHODS: Multivariable logistic regression models were estimated to predict the likelihood of prostate cancer diagnosis on first biopsy for 75,295 Black and 207,658 White male veterans. Self-identified race, age at first PSA test, prebiopsy PSA, age at first biopsy, smoking status, statin use, and socioeconomic factors were used as predictors. The adjusted predicted probabilities of cancer detection on first prostate biopsy from the logistic models at different PSA levels were calculated.
RESULTS: After controlling for PSA and other covariates, Black veterans were 50% more likely to receive a prostate cancer diagnosis on their first prostate biopsy than White veterans (odds ratio [OR], 1.50; 95% CI, 1.47-1.53; p < .001). At a PSA level of 4.0 ng/mL, the probability of prostate cancer for a Black man was 49% compared with 39% for a White man. This model indicated that Black veterans with a PSA of 4.0 ng/mL have an equivalent risk of prostate cancer as White veterans with a PSA of 13.4 ng/mL.
CONCLUSIONS: The findings indicate that, at any given PSA level, Black men are more likely to harbor prostate cancer than White men. Prospective studies are needed to better evaluate risks and benefits of PSA screening in Black men and other high-risk populations.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:130 |
|---|---|
| Enthalten in: |
Cancer - 130(2024), 2 vom: 15. Jan., Seite 224-231 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Kyung Min [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biopsy |
|---|
| Anmerkungen: |
Date Completed 23.01.2024 Date Revised 11.03.2024 published: Print-Electronic CommentIn: Cancer. 2024 Jan;130(2):179-181. - PMID 37927174 Citation Status MEDLINE |
|---|
| doi: |
10.1002/cncr.34979 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364189509 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364189509 | ||
| 003 | DE-627 | ||
| 005 | 20240311231939.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cncr.34979 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1323.xml |
| 035 | |a (DE-627)NLM364189509 | ||
| 035 | |a (NLM)37927109 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Kyung Min |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association between prediagnostic prostate-specific antigen and prostate cancer probability in Black and non-Hispanic White men |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.01.2024 | ||
| 500 | |a Date Revised 11.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Cancer. 2024 Jan;130(2):179-181. - PMID 37927174 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 American Cancer Society. | ||
| 520 | |a BACKGROUND: Although Black men are more likely than non-Hispanic White men to develop and die from prostate cancer, limited data exist to guide prostate-specific antigen (PSA) screening protocols in Black men. This study investigated whether the risk for prostate cancer was higher than expected among self-identified Black than White veterans based on prebiopsy PSA level | ||
| 520 | |a METHODS: Multivariable logistic regression models were estimated to predict the likelihood of prostate cancer diagnosis on first biopsy for 75,295 Black and 207,658 White male veterans. Self-identified race, age at first PSA test, prebiopsy PSA, age at first biopsy, smoking status, statin use, and socioeconomic factors were used as predictors. The adjusted predicted probabilities of cancer detection on first prostate biopsy from the logistic models at different PSA levels were calculated | ||
| 520 | |a RESULTS: After controlling for PSA and other covariates, Black veterans were 50% more likely to receive a prostate cancer diagnosis on their first prostate biopsy than White veterans (odds ratio [OR], 1.50; 95% CI, 1.47-1.53; p < .001). At a PSA level of 4.0 ng/mL, the probability of prostate cancer for a Black man was 49% compared with 39% for a White man. This model indicated that Black veterans with a PSA of 4.0 ng/mL have an equivalent risk of prostate cancer as White veterans with a PSA of 13.4 ng/mL | ||
| 520 | |a CONCLUSIONS: The findings indicate that, at any given PSA level, Black men are more likely to harbor prostate cancer than White men. Prospective studies are needed to better evaluate risks and benefits of PSA screening in Black men and other high-risk populations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a biopsy | |
| 650 | 4 | |a prostate cancer | |
| 650 | 4 | |a prostate-specific antigen | |
| 650 | 7 | |a Prostate-Specific Antigen |2 NLM | |
| 650 | 7 | |a EC 3.4.21.77 |2 NLM | |
| 700 | 1 | |a Bryant, Alex K |e verfasserin |4 aut | |
| 700 | 1 | |a Lynch, Julie A |e verfasserin |4 aut | |
| 700 | 1 | |a Robison, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Alba, Patrick R |e verfasserin |4 aut | |
| 700 | 1 | |a Agiri, Fatai Y |e verfasserin |4 aut | |
| 700 | 1 | |a Pridgen, Kathryn M |e verfasserin |4 aut | |
| 700 | 1 | |a DuVall, Scott L |e verfasserin |4 aut | |
| 700 | 1 | |a Yamoah, Kosj |e verfasserin |4 aut | |
| 700 | 1 | |a Garraway, Isla P |e verfasserin |4 aut | |
| 700 | 1 | |a Rose, Brent S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer |d 1948 |g 130(2024), 2 vom: 15. Jan., Seite 224-231 |w (DE-627)NLM000028649 |x 1097-0142 |7 nnns |
| 773 | 1 | 8 | |g volume:130 |g year:2024 |g number:2 |g day:15 |g month:01 |g pages:224-231 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cncr.34979 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 130 |j 2024 |e 2 |b 15 |c 01 |h 224-231 | ||